Table 2.
Tumor nuclear CSE1L expression and clinical parameters in CRC
| |
Nuclear CSE1L |
Total |
P |
|
|---|---|---|---|---|
| Low (1+) | High (2+ or 3+) | |||
| Sex |
|
|
|
|
| female |
33 (63.5) # |
19 (36.5) |
52 |
0.099 |
| male |
37 (48.7) |
39 (51.3) |
76 |
|
| Grade |
|
|
|
|
| well |
3 (75) |
1 (25) |
4 |
0.699 |
| moderate |
63 (53.8) |
54 (46.2) |
117 |
|
| poor |
4 (57.1) |
3 (42.9) |
7 |
|
| T status |
|
|
|
|
| T1+T2 |
13 (61.9) |
8 (38.1) |
21 |
0.467 |
| T3+T4 |
57 (53.3) |
50 (46.7) |
107 |
|
| Lymph node metastasis |
|
|
|
|
| no |
40 (53.3) |
35 (46.7) |
75 |
0.714 |
| yes |
30 (56.6) |
23 (43.4) |
53 |
|
| Distance metastasis |
|
|
|
|
| no |
62 (55.9) |
49 (44.1) |
111 |
0.497 |
| yes |
8 (47.1) |
9 (52.9) |
17 |
|
| Stage |
|
|
|
|
| I |
12 (60) |
8 (40) |
20 |
0.346 |
| II |
23 (47.9) |
25 (52.1) |
48 |
|
| III |
28 (63.6) |
16 (36.4) |
44 |
|
| IV |
7 (43.8) |
9 (56.2) |
16 |
|
| Stage |
|
|
|
|
| I/ II |
35 (51.5) |
33 (48.5) |
68 |
0.436 |
| III/IV |
35 (58.3) |
25 (41.7) |
60 |
|
| Overall survival |
|
|
|
|
| ≤5 y |
39 (52.7) |
35 (47.3) |
74 |
0.579 |
| ≥5 y | 31 (57.4) | 23 (42.6) | 54 | |
Data are shown as number of cases (%).